Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,685 stopped studies mapped to Malignant Thoracic Neoplasm and descendants · 90% state a reason
Over the 1,685 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or… | Phase 1 / Phase 2 | terminated | Jan 20, 2017 | AbbVie | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. | Safety / toxicity |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab…(RATIONALE001) | Phase 3 | terminated | Nov 19, 2018 | Celgene | BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound,… | Other (stated, no rule matched) |
| NCT00840749 | Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell…(STARS) | N/A | terminated | Feb 10, 2009 | Accuray Incorporated | Lack of enrollment | Enrollment / accrual |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Phase 2 | terminated | Jul 17, 2014 | Washington University School of Medicine | Terminated by sponsor | Other (stated, no rule matched) |
| NCT03330834 | CAR-T Cell Immunotherapy for Advanced Lung Cancer | Phase 1 | terminated | Nov 6, 2017 | Sun Yat-sen University | Serious adverse events | Safety / toxicity |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell…(EVENT) | Phase 2 | terminated | May 20, 2013 | Albert Einstein College of Medicine | low accrual | Enrollment / accrual |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating… | Phase 2 | terminated | Mar 4, 2013 | University of Chicago | Due to lack of activity and slow accrual | Enrollment / accrual |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy…(IDA) | Phase 3 | terminated | Dec 9, 2013 | Norwegian University of Science and Technology | Poor enrollment due to the introduction of immunotherapy | Enrollment / accrual |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants… | Phase 2 | withdrawn | Jul 13, 2016 | Eli Lilly and Company | To pursue broader program objectives in oncology. | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small… | Phase 3 | withdrawn | Dec 18, 2019 | Incyte Corporation | Sponsor Strategic/Business Decision | Sponsor / business decision |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Phase 2 | terminated | Jan 26, 2018 | Agenus Inc. | Trial will not proceed due to changes in the treatment landscape. | Other (stated, no rule matched) |
| NCT03713099 | NEUWAVE Flexible Probe Study #2 | N/A | withdrawn | Oct 19, 2018 | Ethicon, Inc. | Changed study design prior to any patients enrolled. | Enrollment / accrual |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | Phase 2 | terminated | Jan 11, 2007 | NewLink Genetics Corporation | Enrollment goals unable to be reached. | Enrollment / accrual |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | Phase 1 | terminated | Aug 22, 2008 | NewLink Genetics Corporation | Lack of enrollment. | Enrollment / accrual |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | terminated | Jan 24, 2013 | NewLink Genetics Corporation | not stated | Not stated |
| NCT02115464 | Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy(ALMERA) | Phase 2 | terminated | Apr 16, 2014 | Ontario Clinical Oncology Group (OCOG) | The accrual rate was not high enough to reach the target sample size. | Enrollment / accrual |
| NCT03267368 | Comprehensive Care Program SBRT | N/A | terminated | Aug 30, 2017 | Corewell Health East | Low enrollment. 1 pt. enrolled \& withdrew at 6 wk follow-up. No further enrollment | Enrollment / accrual |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT03574220 | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung… | Early Phase 1 | withdrawn | Jun 29, 2018 | Case Comprehensive Cancer Center | No accrual - closed by PRMC | Enrollment / accrual |
| NCT03674450 | Lung Heart Rate Variability(HRV) | N/A | withdrawn | Sep 17, 2018 | Abramson Cancer Center at Penn Medicine | This study never enrolled any subjects. It was terminated due to staffing and technology changes. | Enrollment / accrual |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in… | Phase 2 | terminated | May 22, 2015 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT00955942 | Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small… | Phase 1 | terminated | Aug 10, 2009 | Abramson Cancer Center at Penn Medicine | Insufficient enrollment | Enrollment / accrual |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous… | Phase 1 | withdrawn | Jun 28, 2011 | Mayo Clinic | lack of access to study drug | Other (stated, no rule matched) |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent… | Phase 1 | withdrawn | Jan 8, 2009 | University of Maryland, Baltimore | There was no patient accrual nor study activity due to inability to fund PFTs. | Enrollment / accrual |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Jul 9, 2018 | Regeneron Pharmaceuticals | Program reprioritization | Other (stated, no rule matched) |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03763851 | Cannabis Oil and Radiation Therapy for the Management of Pain | Phase 2 | terminated | Dec 4, 2018 | Tetra Bio-Pharma | due to mycotoxin potential contamination of one lot of study drug | Other (stated, no rule matched) |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Phase 2 | terminated | Oct 30, 2012 | Mayo Clinic | Poor accrual and funding ended | Enrollment / accrual |
| NCT03302221 | Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave… | Phase 4 | withdrawn | Oct 5, 2017 | China Medical University, China | No participants enrolled | Enrollment / accrual |
| NCT03198117 | Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small… | N/A | terminated | Jun 23, 2017 | Qidong Gaitianli Medicines Co., Ltd | Difficulty in patient recruitment | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT03460678 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of… | Phase 4 | terminated | Mar 9, 2018 | Hikma Pharmaceuticals LLC | Difficulty recruiting | Enrollment / accrual |
| NCT03678090 | The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter… | Phase 2 | withdrawn | Sep 19, 2018 | Yale University | Local IRB recommended IND exemption from FDA, study timeline not able to be met. | Other (stated, no rule matched) |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT03524248 | Development of Real-time Image-guided Radiotherapy | N/A | terminated | May 14, 2018 | Fox Chase Cancer Center | Camera for study is being repaired | Other (stated, no rule matched) |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab,…(iTRAP) | Phase 1 | withdrawn | Apr 13, 2018 | Queen Mary University of London | Funder and IMP manufacturer withdrew support | Drug supply |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | N/A | terminated | Mar 20, 2012 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared… | Phase 1 | terminated | Jun 11, 2015 | Novartis Pharmaceuticals | Major challenge for enrollment of participants. | Enrollment / accrual |
| NCT03589456 | Establishment of a PDT Patient Registry | — | terminated | Jul 17, 2018 | Concordia Laboratories Inc. | Study was closed to accrual on January 15, 2020. | Enrollment / accrual |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For… | Phase 2 | terminated | Jun 11, 2015 | howard safran | Lack of accrual | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Phase 2 | terminated | Apr 17, 2014 | Heat Biologics | Sponsor Decision; strategic - based on changing treatment landscape | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jul 17, 2020source: clinicaltrials